Precision Medicine in Oncology® | Specialty

Case Study: Treating KRAS-Mutant Adenocarcinoma

August 21st 2013

Case Study: Progression on ALK Inhibitors in NSCLC

August 21st 2013

Case Study: MET and ALK Targeted Therapies in NSCLC

August 21st 2013

Case Study: Second-Line Treatment of Adenocarcinoma

August 21st 2013

PRONOUNCE Trial: Two Drug Versus Three Drug Regimens

August 21st 2013

Case Study: Mutation-Negative Patient With Adenocarcinoma

August 21st 2013

Case Study: Maintenance Therapy in Squamous NSCLC

August 21st 2013

Case Study: Treating an Elderly Patient With Squamous NSCLC

August 21st 2013

The Urologist in the World of Personalized Medicine

August 21st 2013

We should move away from directing therapy based on the primary site of malignancy and focus our efforts on inherent pathways common to the tumors, irrespective of the organ.

Big Ten Cancer Centers Form Research Group

August 20th 2013

While competition is the hallmark of the powerhouse sports teams of the Big Ten Conference, collaboration will be the key for a research initiative recently launched by cancer centers at most of the same universities.

Exploring Tumors in Context: Jain's Work Blazes Trail on Microenvironment

August 16th 2013

An interview with Rakesh K. Jain, PhD, a cancer researcher focused on pathophysiology who helped establish the role of the tumor microenvironment in the treatment of cancer.

More Genetic Screening Needed for African-American Breast Cancer Patients

August 15th 2013

One in five African-American women with breast cancer carries an abnormality in at least one gene associated with breast cancer susceptibility.

Dr. Langer Discusses Afatinib in EGFR-Positive NSCLC

August 13th 2013

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses integrating the irreversible pan-HER inhibitor afatinib into the treatment paradigm for patients with advanced non-small cell lung cancer.

Dr. Van Tine on Identifying Biomarkers in Sarcomas

August 12th 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Challenges Still Abound in Antibody Therapeutics

August 8th 2013

An interview with Andrew Scott, MB,BS, MD, whose work has led to the successful translation of novel potential cancer therapeutics into clinical development.

Dr. Saenger on the Need for Immunotherapy Biomarkers

August 7th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

Tamoxifen Significantly Lowers Risk of Contralateral Breast Cancer in BRCA-Positive Patients

August 6th 2013

Patients with mutations of BRCA1 or BRCA2 who received tamoxifen after their initial diagnosis of breast cancer reduced their chances of developing contralateral or secondary breast cancer by more than half.

The Antibody Arsenal: More Complex Targeted Agents Primed for Increased Potency

August 6th 2013

More than a century has passed since the discovery of antibodies and thanks to a number of Nobel Prize-winning scientists, we have begun to realize their potential as therapeutic tools in cancer.

Cabozantinib Benefit Greater in MTC Patients With RET and RAS Mutations

August 1st 2013

A detailed analysis of previously reported data on the multikinase inhibitor cabozantinib in medullary thyroid cancer found that patients with mutations of RET and RAS experienced a significantly higher benefit than patients without those mutations.

RAS Mutation Status Key to Panitumumab Use in mCRC

July 30th 2013

The presence or absence of RAS mutations should dictate use of panitumumab in combination with FOLFOX chemotherapy for patients with metastatic colorectal cancer.